Press Releases
Mar 11, 2024

Designation follows December 2023 FDA approval for the treatment of these serious, potentially life-threatening fungal infections in children CRESEMBA receives seven years and six months of US...

Mar 3, 2024

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced dosing of the first patient in the STARLIGHT™ 2 Phase 3 pivotal study for fezolinetant, an...

Feb 22, 2024

Today, Astellas Pharma Inc. Chief Commercial Officer Claus Zieler has named Michael Petroutsas as Head, United States Commercial, leading the Astellas Pharma US Inc. organization. Petroutsas will...

EXPLORE ALL US PRESS RELEASES

Articles
Feb 8, 2024

As a civilian partner working for the Army for many years following his time in Vietnam, Jim didn’t suspect anything was amiss when he went for his annual health exam in 2006. However, during...

Dec 15, 2023

Astellas is proud to be featured on the Human Rights Campaign Foundation’s (HRC) annual Corporate Equality Index (CEI) for its continued support of the LGBTQ+ community within the workplace....

Oct 10, 2023

Astellas ranked in Seramount’s 2023 “100 Best Companies” list for the ninth consecutive year This year, Astellas once again was named as a top company for working parents on Seramount’s...

EXPLORE ALL ARTICLES

Stay Connected

Get only the email alerts you want.

Subscribe

Media Contacts

 

For media inquiries and reporter requests, please click here to fill out a request form.

Our communications team will respond to verified media requests within 24-48 hours as appropriate.

If you are not a reporter and need assistance, please visit our contact us page that includes information for patients, healthcare providers and researchers.

 

Astellas on Twitter
Download Fact Sheet
Sustainability
Investors
Explore U.S. Products